These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750 [TBL] [Abstract][Full Text] [Related]
23. Stereotactic Radiation Therapy Combined With Immunotherapy Against Metastatic Melanoma: Long-Term Results of a Phase 1 Clinical Trial. Ratnayake G; Reinwald S; Shackleton M; Moore M; Voskoboynik M; Ruben J; van Zelm MC; Yu D; Ward R; Smith R; Haydon A; Senthi S Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):150-156. PubMed ID: 32450331 [TBL] [Abstract][Full Text] [Related]
24. Treatment outcomes of stereotactic ablative body radiotherapy on oligometastases from colorectal cancer: early results of a single institution service evaluation. Duong J; Stewart-Lord A; Nariyangadu P; Harrison M; Tsang YM BJR Open; 2022; 4(1):20210071. PubMed ID: 36105422 [TBL] [Abstract][Full Text] [Related]
25. The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma. Franzese C; Marini B; Baldaccini D; Badalamenti M; Navarria P; Bellu L; Franceschini D; Comito T; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Lo Faro L; Tomatis S; Scorsetti M J Cancer Res Clin Oncol; 2023 Jul; 149(8):4411-4417. PubMed ID: 36109401 [TBL] [Abstract][Full Text] [Related]
26. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature. Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035 [TBL] [Abstract][Full Text] [Related]
27. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. Phillips R; Shi WY; Deek M; Radwan N; Lim SJ; Antonarakis ES; Rowe SP; Ross AE; Gorin MA; Deville C; Greco SC; Wang H; Denmeade SR; Paller CJ; Dipasquale S; DeWeese TL; Song DY; Wang H; Carducci MA; Pienta KJ; Pomper MG; Dicker AP; Eisenberger MA; Alizadeh AA; Diehn M; Tran PT JAMA Oncol; 2020 May; 6(5):650-659. PubMed ID: 32215577 [TBL] [Abstract][Full Text] [Related]
28. Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. Comito T; Cozzi L; Clerici E; Campisi MC; Liardo RL; Navarria P; Ascolese A; Tozzi A; Iftode C; De Rose F; Villa E; Personeni N; Rimassa L; Santoro A; Fogliata A; Mancosu P; Tomatis S; Scorsetti M BMC Cancer; 2014 Aug; 14():619. PubMed ID: 25163798 [TBL] [Abstract][Full Text] [Related]
29. Long-term toxicity and survival outcomes after stereotactic ablative radiotherapy for patients with centrally located thoracic tumors. Atalar B; Mustafayev TZ; Sio TT; Sahin B; Gungor G; Aydın G; Yapici B; Ozyar E Radiol Oncol; 2020 Jun; 54(4):480-487. PubMed ID: 32589607 [TBL] [Abstract][Full Text] [Related]
30. Stereotactic ablative radiosurgery for locally advanced or recurrent skull base malignancies with prior external beam radiation therapy. Xu KM; Quan K; Clump DA; Ferris RL; Heron DE Front Oncol; 2015; 5():65. PubMed ID: 25853093 [TBL] [Abstract][Full Text] [Related]
31. Salvage stereotactic ablative body radiotherapy after thermal ablation of primary kidney cancer. Ali M; Kwon YS; Koo K; Bruynzeel A; Pryor D; Schep DG; Huo M; Stein M; Swaminath A; Hannan R; Siva S BJU Int; 2025 Jan; 135(1):110-116. PubMed ID: 39187428 [TBL] [Abstract][Full Text] [Related]
32. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up. Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627 [TBL] [Abstract][Full Text] [Related]
33. Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer. Wijetunga NA; Dos Anjos CH; Zhi WI; Robson M; Tsai CJ; Yamada Y; Dover L; Gillespie EF; Xu AJ; Yang JT Cancer Med; 2021 Aug; 10(15):5163-5174. PubMed ID: 34159748 [TBL] [Abstract][Full Text] [Related]
34. A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol. Palma DA; Giuliani ME; Correa RJM; Schneiders FL; Harrow S; Guckenberger M; Zhang T; Bahig H; Senthi S; Chung P; Olson R; Lock M; Raman S; Bauman GS; Lok BH; Laba JM; Glicksman RM; Nguyen TK; Lang P; Helou J; Goodman CD; Mendez LC; van Rossum PSN; Warner A; Gaede S; Allan AL BMC Palliat Care; 2024 Sep; 23(1):223. PubMed ID: 39244532 [TBL] [Abstract][Full Text] [Related]
35. Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease. Salim N; Tumanova K; Popodko A; Libson E JCO Glob Oncol; 2024 May; 10():e2300275. PubMed ID: 38754052 [TBL] [Abstract][Full Text] [Related]
36. Stereotactic ablative body radiotherapy (SABR) for effective palliation of metastases: factors affecting local control. Patel PR; Kirkpatrick J; Salama JK; Nelson J; Broadwater G; Allen K; Clough R; Yin FF; Wang Z; Chang Z; Kelsey C; Ghafoori AP J Radiosurg SBRT; 2014; 3(2):123-129. PubMed ID: 29296393 [TBL] [Abstract][Full Text] [Related]
37. Stereotactic Ablative Radiation Therapy for Unresectable Colorectal Oligometastases. Sutera P; Kalash R; Clump DA; D'Ambrosio D; Mihai A; Burton SA; Heron DE Adv Radiat Oncol; 2019; 4(1):57-62. PubMed ID: 30706011 [TBL] [Abstract][Full Text] [Related]
38. Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR). Franzese C; Vernier V; Franceschini D; Comito T; Navarria P; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Marini B; Galdieri C; Mancosu P; Tomatis S; Scorsetti M J Cancer Res Clin Oncol; 2023 Sep; 149(12):10495-10503. PubMed ID: 37280407 [TBL] [Abstract][Full Text] [Related]
39. Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization. Lee HL; Tsai JT; Chen CY; Lin YC; Ho CB; Ting LL; Kuo CC; Lai IC; Lin CY; Tang JH; Huang YM; Kao WY; Cheng SW; Shen CN; Chen SW; Chiou JF Ther Adv Med Oncol; 2019; 11():1758835919889002. PubMed ID: 31839809 [TBL] [Abstract][Full Text] [Related]
40. Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity. Goldsmith C; Plowman PN; Green MM; Dale RG; Price PM Radiat Oncol; 2018 Oct; 13(1):204. PubMed ID: 30340643 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]